

**Docket #:** S25-471

# **Chaperone-inspired Biologics for Suppression of HTT Aggregation and Toxicity**

Huntington's Disease and other ataxias are devastating diseases without any cure or treatment. They are caused by the formation of toxic oligomeric and the aggregation of the Huntingtin (HTT) protein. A mutation in the HTT exon involving a polyglutamine expansion beyond 36 consecutive glutamines promotes the formation of amyloid-like fibers and results in disease. To date, there are no available treatments to prevent the aggregation and toxicity of the HTT protein or to treat the mutation.

The Frydman Lab at Stanford has synthesized a set of endogenous chaperones that can prevent HTT aggregation and toxicity. These biologics target the HTT-binding domains to prevent mutant HTT aggregation and toxicity. The binding regions of the constructs can also be modified so they can be used as small molecules to target different HTT regions. Delivery of the biologics can be achieved by using existing brain-penetrant strategies, such as adeno-associated virus vectors (AAV), nanoparticles, etc. The invention could also be applied to increase the chaperone capacity of cells and aid in other types of protein aggregation diseases.

## **Stage of Development**

Research - in vitro

## **Applications**

- Small molecule biologic
- Genetic disorders
- Protein-folding disorders

## **Advantages**

- There are no currently available treatments that prevent Htt toxicity or aggregation in patients
- Compatible with existing delivery platforms
- Could be modified to target other genetic disorders involving protein aggregation

## **Innovators**

- Judith Frydman
- Korbin Kleczko

## **Licensing Contact**

### **Inyoung Lee**

Licensing Manager, Life Sciences

[Email](#)